CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Amy Schumer opened up about taking Ozempic and losing 30 pounds. She also shared that she was “bedridden” with nausea, which is why she ultimately stopped taking the medication. “But other people take ...